Taiwan · Delayed Price · Currency is TWD BIONET Statistics
Total Valuation
BIONET has a market cap or net worth of TWD 5.50 billion. The enterprise value is 5.05 billion.
| Market Cap | 5.50B |
| Enterprise Value | 5.05B |
Important Dates
The next estimated earnings date is Tuesday, November 11, 2025.
| Earnings Date | Nov 11, 2025 |
| Ex-Dividend Date | Oct 3, 2025 |
Share Statistics
BIONET has 53.12 million shares outstanding. The number of shares has increased by 0.08% in one year.
| Current Share Class | 53.12M |
| Shares Outstanding | 53.12M |
| Shares Change (YoY) | +0.08% |
| Shares Change (QoQ) | -0.39% |
| Owned by Insiders (%) | 8.99% |
| Owned by Institutions (%) | 1.62% |
| Float | 41.72M |
Valuation Ratios
The trailing PE ratio is 73.90.
| PE Ratio | 73.90 |
| Forward PE | n/a |
| PS Ratio | 4.48 |
| PB Ratio | 2.43 |
| P/TBV Ratio | 4.47 |
| P/FCF Ratio | 90.53 |
| P/OCF Ratio | 33.73 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 72.57, with an EV/FCF ratio of 83.23.
| EV / Earnings | 71.04 |
| EV / Sales | 4.12 |
| EV / EBITDA | 72.57 |
| EV / EBIT | 201.57 |
| EV / FCF | 83.23 |
Financial Position
The company has a current ratio of 4.43, with a Debt / Equity ratio of 0.02.
| Current Ratio | 4.43 |
| Quick Ratio | 4.14 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | 0.59 |
| Debt / FCF | 0.67 |
| Interest Coverage | 18.11 |
Financial Efficiency
Return on equity (ROE) is 1.30% and return on invested capital (ROIC) is 0.70%.
| Return on Equity (ROE) | 1.30% |
| Return on Assets (ROA) | 0.53% |
| Return on Invested Capital (ROIC) | 0.70% |
| Return on Capital Employed (ROCE) | 0.95% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.42 |
| Inventory Turnover | 6.75 |
Taxes
In the past 12 months, BIONET has paid 31.61 million in taxes.
| Income Tax | 31.61M |
| Effective Tax Rate | 53.06% |
Stock Price Statistics
The stock price has increased by +13.24% in the last 52 weeks. The beta is 0.43, so BIONET's price volatility has been lower than the market average.
| Beta (5Y) | 0.43 |
| 52-Week Price Change | +13.24% |
| 50-Day Moving Average | 82.50 |
| 200-Day Moving Average | 77.29 |
| Relative Strength Index (RSI) | 79.17 |
| Average Volume (20 Days) | 893,327 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BIONET had revenue of TWD 1.23 billion and earned 71.15 million in profits. Earnings per share was 1.40.
| Revenue | 1.23B |
| Gross Profit | 688.12M |
| Operating Income | 25.08M |
| Pretax Income | 59.57M |
| Net Income | 71.15M |
| EBITDA | 57.31M |
| EBIT | 25.08M |
| Earnings Per Share (EPS) | 1.40 |
Balance Sheet
The company has 1.48 billion in cash and 40.77 million in debt, giving a net cash position of 1.44 billion or 27.15 per share.
| Cash & Cash Equivalents | 1.48B |
| Total Debt | 40.77M |
| Net Cash | 1.44B |
| Net Cash Per Share | 27.15 |
| Equity (Book Value) | 2.26B |
| Book Value Per Share | 23.74 |
| Working Capital | 1.48B |
Cash Flow
In the last 12 months, operating cash flow was 162.99 million and capital expenditures -102.25 million, giving a free cash flow of 60.73 million.
| Operating Cash Flow | 162.99M |
| Capital Expenditures | -102.25M |
| Free Cash Flow | 60.73M |
| FCF Per Share | 1.14 |
Margins
Gross margin is 56.04%, with operating and profit margins of 2.04% and 5.79%.
| Gross Margin | 56.04% |
| Operating Margin | 2.04% |
| Pretax Margin | 4.85% |
| Profit Margin | 5.79% |
| EBITDA Margin | 4.67% |
| EBIT Margin | 2.04% |
| FCF Margin | 4.95% |
Dividends & Yields
This stock pays an annual dividend of 1.42, which amounts to a dividend yield of 1.37%.
| Dividend Per Share | 1.42 |
| Dividend Yield | 1.37% |
| Dividend Growth (YoY) | 99.69% |
| Years of Dividend Growth | 4 |
| Payout Ratio | 46.60% |
| Buyback Yield | -0.08% |
| Shareholder Yield | 1.29% |
| Earnings Yield | 1.29% |
| FCF Yield | 1.10% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on September 19, 2024. It was a forward split with a ratio of 1.070923771.
| Last Split Date | Sep 19, 2024 |
| Split Type | Forward |
| Split Ratio | 1.070923771 |
Scores
BIONET has an Altman Z-Score of 4.36 and a Piotroski F-Score of 6.
| Altman Z-Score | 4.36 |
| Piotroski F-Score | 6 |